Member Info for nursesteve

🪄 ✨ They're hard at work ‘just getting on with it’ and soon we will see exactly what they’ve been working on without the RNS wrappers! 🎁

Let’s hope we get the reward that we faithful believers in the ‘big guy’ have been promised. It is the commercialisation season after all! GLA

I think we are due the news we have been waiting on very soon. Hence my top up this morning which is showing as a sell ( 10:06:34 138.45 1,438 Sell* 1,991). Would have been nicer to top up a little bit lower (like I did last week at 1.29) but I’m happy with my holding here. GLALTH 👍🏻

That’s very narrow minded Slacker246. The potential market in the UK if the PSE test were to be used as part of a national screening program is not inconsiderable and the adoption of such a test would be a way to introduce consideration of the other company products.

I’ve emailed the company myself and will share the reply I get.

Thanks for your contributions DugWalker.

It would be great if the company announced they were participating in the Transform trial or at least answer if not why not? If emailed would they need to answer via an RNS?

I think that the PSE test is good enough to be part of a national screening program and certainly very valuable from individual patients point of view. IMHO this will be a key revenue generator for the company and a gateway to the other tests the company has. So I’m invested and holding here.

I know enough to be invested here! 😀 GLA

So we are awaiting the full release of the data from the AVA6000 trial so far which is being done to show the wider communities Pharma and II what is behind and backs up the hyperbole in the previous company statements. If (as expected) this is as good as we faithful SH think then what do we think will be next? Partnership agreements? Licensing agreements? A TO offer? Some TR1’s? 🤔

The trial for prostate screening shows the government are willing to invest in Prostate screening. As the title of this thread states “when the facts change” surely the organisers can and should consider including the PSE test with the justification being the objective of the trial is now mute based on the new evidence (on PSE effectiveness) ?

The company could also offer to provide the test for evaluation alongside the other methods being used if the organisers can’t accept the efficacy data already available ?

& good luck amigos

It would be surprising if NICE didn’t recommend that the PSE test be used for screening men at risk from Prostate cancer. So it’s just a question of when IMHO and if / when that happens we will see more focus on their other available tests.

Good news today as regulators have approved a novel treatment for sickle cell disease and beta thalassemia which is the first to be licensed using the gene-editing tool known as Crispr. The results have been described as a potential cure!

Let’s hope the same phrase can be applied to AVA6000 in STS

I did notice an article in the Telegraph newspaper about about MHRA reforms.

"Although applications should be assessed within 30 days, the average wait hit four months earlier this year following a surge of applications. In an average year, the MHRA normally approves around 750 new trials per year. Since July, it has approved 2,200, wiping out a backlog of almost 1,000."

https://www.telegraph.co.uk/news/2023/11/11/life-saving-drug-trials-go-ahead-faster-uk-brexit/

Maybe those reforms will help speeds things up? 🤔

I messaged my local NHS surgery to ask if the PSE test was available (I’m in the age range where it’s recommended I get checked). My GP replied that as the sample size was quite small it was yet being offered and the regulatory authorities are awaiting for the results on a larger sample size before the test is released on the NHS. So it seems to be just a question when and how long that might take now? Especially as he seemed to indicate he’d favour being able to offer it as he added that unfortunately a prostate examination and a PSA test are still the current modes of diagnosing Prostate cancer for now.

I also think it’s interesting that the percentage they bought is just below what it would take for them to have to make an offer?

In the RNS released in May - ‘Avani now owns 29.86 per cent. of the existing Ordinary Shares in the Company (the "Ordinary Shares"). The transaction was undertaken on 10 May 2023 at a price of 18p per share (the "Transaction"). The Transaction was conducted off-market and will settle on 12 May 2023’.

18p is a lot higher than my average so I’m still holding on to my shares as Avani would have more insight into the company than I have.

His specific focus will be to grow sales in the US market, where he has considerable experience of launching products. Excellent appointment and great to see them focusing on this sizeable market.

Just added another 5000 myself 😁

Bella nice link to the different types of peer reviews. Thanks.

I think they might publish the data and go for a post published peer or open review.

Or leek?

Not the best follow up RNS but a good opportunity to buy on the dip